An interventional study of Neurological examinations and Neuropsychological examinations in Patients With Cognitive Disturbances, sponsored by Centre Hospitalier St Anne. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Basic science
Hippocampal Sclerosis (HS) leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.
Hippocampal sclerosis (HS) refers to neuronal cell loss and astrocytosis in subiculum and cornu ammonis subfields of the hippocampal formation unrelated to Alzheimer's disease pathology. In contrast to HS that affects younger adults with epilepsy, older individuals with HS have significant ante-mortem cognitive dysfunction but no epilepsy. Neuropathological studies demonstrated three main types of HS associated with aging: (a) HS-Ageing to refer to the disease with HS pathology in ageing individuals, observed in more than 10% of subjects aged over 85 years; (b) HS observed in the behavioural variant of frontotemporal dementia (bvFTD), HS being more frequent in tau-negative pathology, especially in FTLD-TDP. bvFTD patients may manifest severe episodic memory impairment and hippocampal atrophy; (c) HS associated with cortical or subcortical cerebral microinfarcts, which are invisible on conventional MRI. Cerebral microinfarcts are observed in 33% of elderly over 85 years in post-mortem studies.
HS leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.
22 studies on the registry are indexed under Amnesia; 2 are open to participants now.
This study's enrollment of 141 is above the median of 62 across 19 interventional studies indexed under Amnesia.
Browse Amnesia studies →Centre Hospitalier St Anne is the lead sponsor of 101 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General inclusion criteria
Patients with Hippocampal sclerosis non AD (n=40)
Clinical criteria :
Biological criteria : Absence of Profile suggestive of AD on the study of the biomarkers of the CSF (IATI ratio > 0.8)
Patients with Alheimer's Disase (n=40)
Clinical criteria :
Biological criteria : CSF biomarkers suggestive of AD defined on CSF.
Patients with DLFT (n=20) :
Clinical criteria :
Patients with CBD/PSP (n=20) (Armstrong et al., 2013)
Corticobasal syndrome :
Progressive supranuclear palsy syndrome :
Normal controls (n=20):
Absence of known psychiatric disorder Score on the Folstein Mini Mental Status ( > or = 27) Normal neuropsychological assessment for the age and the educational level
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Hippocampal sclerosis non AD (n=40)
Other: Neurological examinations · Other: Neuropsychological examinations · Other: Clinical examinations · Radiation: MRI 3T · Radiation: MRI 7T
Patients with Alhzeimer's Disase (n=40)
Other: Neurological examinations · Other: Neuropsychological examinations · Other: Clinical examinations · Radiation: MRI 3T · Radiation: MRI 7T
Patients with DLFT (n=20)
Other: Neurological examinations · Other: Neuropsychological examinations · Other: Clinical examinations · Radiation: MRI 3T · Radiation: MRI 7T
Patients with CBD/PSP (n=20)
Other: Neurological examinations · Other: Neuropsychological examinations · Other: Clinical examinations · Radiation: MRI 3T · Radiation: MRI 7T
Normal controls (n=20)
Other: Neurological examinations · Other: Neuropsychological examinations · Other: Clinical examinations · Radiation: MRI 3T · Radiation: MRI 7T
7 tesla MRI.
Structural morphometric analysisze of hippocampal and Papez circuit sub-regions, and detection of microinfarcts/microbleeds by 7 tesla MRI.
Time frame: up to Month 18
3T MRI
Morphometry of hippocampus by 3T MRI
Time frame: Baseline
3T MRI
Morphometry of hippocampus by 3T MRI
Time frame: Month 12
3T MRI
Morphometry of hippocampus by 3T MRI
Time frame: Month 24
3T MRI
White matter intensities assessed by 3T MRI
Time frame: Baseline
3T MRI
White matter intensities assessed by 3T MRI
Time frame: Month 12
3T MRI
White matter intensities assessed by 3T MRI
Time frame: Month 24
7T MRI
Volumetry of the cholinergic nucleus basalis by 7T MRI
Time frame: up to Month 18
CSF
CSF biomarkers
Time frame: Baseline
Neuropsychological assessment
Neuropsychological assessment
Time frame: Baseline
Neuropsychological assessment
Neuropsychological assessment
Time frame: Month 12
Neuropsychological assessment
Neuropsychological assessment
Time frame: Month 24
Clinical assessment
Clinical assessment
Time frame: M0
Clinical assessment
Clinical assessment
Time frame: Month 12
Clinical assessment
Clinical assessment
Time frame: Month 24
Genetic markers of bvFTD
Genetic markers of bvFTD
Time frame: Baseline
Blood markers
Blood markers
Time frame: Baseline
Plasmatic progranulin levels
Plasmatic progranulin levels
Time frame: Baseline
Regional glucose hypometabolism
Regional glucose hypometabolism assessed by FDG-PET (if performed during clinical care).
Time frame: Baseline
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.